Fosmanogepix is an experimental antifungal drug being developed by Amplyx Pharmaceuticals (now currently by Pfizer and Basilea[1][2]) It is being investigated for its potential to treat various fungal infections including aspergillosis, candidaemia, and coccidioidomycosis.

[3] Fosmanogepix is a prodrug and is converted into the active drug form, manogepix in vivo.

[6] Inhibiting this enzyme prevents the fungi from properly modifying certain (so called GPI-anchored) proteins essential to the fungal life cycle.

This mechanism of action is totally novel; therefore, if approved, fosmanogepix would become a first-in-class medication.

[6][7] In 2023, the drug was given a compassionate use authorization for four patients with Fusarium solani meningitis.